Preclinical screening of gene therapy in human tissues

Human Gene Therapy

Volumn 20, Issue 4, 2009, Pages 291-292

  Seymour, Leonard W ^a   Fisher, Kerry D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; C REACTIVE PROTEIN; COMPLEMENT; NUCLEIC ACID; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; EDITORIAL; FLU LIKE SYNDROME; GENE THERAPY; GENE VECTOR; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHAGOCYTE; SPECIES DIFFERENCE; TUMOR XENOGRAFT; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; HUMANS; IMMUNITY, INNATE; MICE; ORGAN SPECIFICITY; VIRUSES;

EID: 64049118518     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.1309     Document Type: Editorial

References (10)

1. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B.J., and Lydon, N.B. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104.
2. Burtles, S.S., Newell, D.R., Henrar, R.E., and Connors, T.A. (1995). Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office. Eur. J. Cancer 31A, 408-410.
3. Carlisle, R.C., Di, Y., Cerny, A.M., Sonnen, A.F., Sim, R.B., Green, N.K., Subr, V., Ulbrich, K., Gilbert, R.J., Fisher, K.D., Finberg, R.W., and Seymour, L.W. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909-1918.
4. Johnson, J.I., Decker, S., Zaharevitz, D., Rubinstein, L.V., Venditti, J.M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., and Sausville, E.A. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431.
5. Kerbel, R.S. (2003). Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, S134-S139.
6. le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., and Gambacorti-Passerini, C. (1999). In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91, 163-168.
7. Newell, D.R., Silvester, J., McDowell, C., and Burtles, S.S. (2004). The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. Eur. J. Cancer 40, 899-906.
8. Seiradake, E., Henaff, D., Wodrich, H., Billet, O., Perreau, M., Hippert, C., Mennechet, F., Schoehn, G., Lortat-Jacob, H., Dreja, H., Ibanes, S., Kalatzis, V., Wang, J.P., Finberg, R.W., Cusack, S., and Kremer, E.J. (2009). The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 5, e1000277.
9. Voskoglou-Nomikos, T., Pater, J.L., and Seymour, L. (2003). Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, 4227-4239.
10. Xu, Z., Tian, J., Smith, J.S., and Byrnes, A.P. (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82, 11705-11713.